title: Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine.
abstract: In 160 high risk patients with total hip replacement the antithrombotic efficacy and tolerance of a single daily injection of 1500 aPTT-U (aPTT = activated partial thromboplastin time) low molecular weight heparin plus 0.5 mg dihydroergotamine (HNMD; Embolex NM) was compared with a twice daily application of 5000 IU of the heparin-dihydroergotamine combination Heparin-Dihydergot in a double-blind study. Deep vein thrombosis measured by means of the radiofibrinogen uptake test occurred in 20.5% of patients in both groups. In addition, intra- and postoperative blood loss and the development of hematoma were similar in both groups. Thus, on account of the "once-daily" application HNMD offers some substantial advantages: The stress of the patient in the postoperative convalescence phase can be appreciably lowered and thereby the nursing staff are spared a great deal of work.
authors.affiliation: Institute for Experimental Surgery, Technical University of Munich, Fed. Rep. of Germany.
authors.forename: S
authors.initials: S
authors.lastname: Haas
authors.forename: A
authors.initials: A
authors.lastname: Stemberger
authors.forename: H M
authors.initials: HM
authors.lastname: Fritsche
authors.forename: D
authors.initials: D
authors.lastname: Welzel
authors.forename: H
authors.initials: H
authors.lastname: Wolf
authors.forename: F
authors.initials: F
authors.lastname: Lechner
authors.forename: G
authors.initials: G
authors.lastname: Blümel
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic; D004087:Dihydroergotamine / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use*; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control; D011897:Random Allocation; D012307:Risk Factors; D013924:Thrombophlebitis / Q000517:prevention & control*
chemical_list: D006495:Heparin, Low-Molecular-Weight; D004087:Dihydroergotamine